As a Free StocksGuide user, you can view scores for all 7,049 stocks worldwide.
12 Analysts have issued a Kyverna Therapeutics forecast:
12 Analysts have issued a Kyverna Therapeutics forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -170 -170 |
41%
41%
|
|
| EBIT (Operating Income) EBIT | -172 -172 |
40%
40%
|
|
| Net Profit | -161 -161 |
45%
45%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
| Head office | United States |
| CEO | Warner Biddle |
| Employees | 129 |
| Founded | 2018 |
| Website | kyvernatx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


